Our Pricing

Understanding Wegovy Or Mounjaro Costs

Published on: June 03, 2026

When comparing wegovy or mounjaro costs uk, understanding the price difference between these two leading weight loss injections helps you make an informed decision. At Cured Pharmacy, Mounjaro (tirzepatide) starts from £124.99 and Wegovy (semaglutide) from £135.00, with transparent upfront pricing and free clinical consultations by UK-registered prescribers.

How Wegovy and Mounjaro Pricing Works in the UK

Both Wegovy and Mounjaro are prescription-only medicines in the UK, licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. Pricing varies based on the prescribed dose strength, treatment duration, and pharmacy dispensing fees.

At Cured Pharmacy, we provide transparent pricing before your consultation begins. Mounjaro costs from £124.99 per pen, whilst Wegovy starts from £135.00 per pen. Your final monthly cost depends on the maintenance dose your UK prescriber determines is clinically appropriate after assessing your medical history, current medications, and weight loss goals.

Unlike some providers, we display exact prices upfront with no hidden consultation fees or subscription charges. Every treatment includes a free online clinical assessment completed in under three minutes, prescription review by a UK-registered prescriber, and discreet next-day delivery across the UK.

Mounjaro Cost Breakdown: What You're Paying For

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed for weight management in the UK [2]. This dual-action mechanism activates two natural hormone pathways that regulate appetite, blood sugar, and energy expenditure, producing significantly greater weight loss than single-pathway treatments in head-to-head clinical trials.

In the SURPASS-2 trial, patients receiving the 15mg tirzepatide dose achieved an average 22.5% body weight reduction over 72 weeks, compared to 15.8% with semaglutide 1mg [2]. The SURMOUNT-1 trial demonstrated that 91% of participants on tirzepatide 15mg achieved at least 5% weight loss, with 57% achieving 20% or greater weight reduction [3].

Mounjaro is administered as a once-weekly subcutaneous injection using a pre-filled KwikPen device. Treatment begins with a 2.5mg starter dose, gradually titrating upwards every four weeks to minimise gastrointestinal side effects. Maintenance doses range from 5mg to 15mg weekly, depending on individual tolerance and weight loss response.

Why Mounjaro Costs More Than Wegovy

The higher cost reflects tirzepatide's dual-receptor mechanism, more recent market entry, and superior weight loss outcomes demonstrated in clinical trials. Mounjaro received UK marketing authorisation in 2023, making it a newer therapeutic option with limited generic competition. Manufacturing costs for dual-agonist peptides are also higher than single-pathway GLP-1 analogues due to increased molecular complexity and production requirements.

Wegovy Cost Breakdown: Semaglutide Pricing Explained

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 to reduce appetite and increase feelings of fullness [4]. Originally developed for type 2 diabetes management as Ozempic, semaglutide was reformulated at higher doses specifically for chronic weight management and licensed by the MHRA in 2022.

The STEP 1 trial demonstrated that adults receiving semaglutide 2.4mg weekly achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [4]. Additionally, 86.4% of participants on semaglutide achieved at least 5% weight loss, meeting the primary efficacy endpoint for obesity pharmacotherapy.

Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled pen. The dosing schedule begins at 0.25mg weekly, increasing every four weeks through 0.5mg, 1mg, and 1.7mg doses before reaching the 2.4mg maintenance dose. This gradual titration minimises common gastrointestinal side effects such as nausea and diarrhoea.

Why Wegovy Costs Less Than Mounjaro

Semaglutide has been available longer than tirzepatide, allowing for more competitive pricing as manufacturing processes mature and market competition increases. The single-receptor mechanism is also less complex to produce than dual-agonist peptides. Wegovy's lower starting price makes it an accessible option for patients seeking clinically proven weight loss outcomes at a more affordable monthly cost.

Which Treatment Offers Better Value for Money?

Determining the best value depends on your individual weight loss goals, budget constraints, and clinical response to treatment. Whilst Mounjaro demonstrates superior weight loss outcomes in clinical trials, Wegovy provides substantial weight reduction at a lower monthly cost, making it suitable for patients with tighter budgets or those seeking proven efficacy without premium pricing.

Consider that greater initial weight loss with Mounjaro may reduce the total treatment duration required to reach your target weight, potentially offsetting the higher per-pen cost. Conversely, Wegovy's lower price point allows for longer treatment courses without financial strain, which may be beneficial for patients requiring extended maintenance therapy to prevent weight regain.

Your UK prescriber will assess your medical history, current BMI, weight-related comorbidities, previous weight loss attempts, and budget considerations during your consultation. They may recommend starting with one treatment and switching if your response is suboptimal or if side effects limit tolerability. Both medications require ongoing clinical monitoring and lifestyle modifications including reduced-calorie diet and increased physical activity.

Factors That Influence Treatment Choice

Clinical factors such as type 2 diabetes status, cardiovascular risk, gastrointestinal tolerance, and previous GLP-1 agonist experience all influence prescriber recommendations. Patients with type 2 diabetes may benefit more from Mounjaro's dual-action mechanism on glucose control, whilst those with previous semaglutide exposure might achieve better outcomes switching to tirzepatide. Your prescriber will weigh these clinical considerations alongside cost to recommend the most appropriate treatment pathway.

Additional Weight Loss Treatment Options at Lower Price Points

If injectable GLP-1 treatments exceed your budget, Cured Pharmacy offers several alternative weight loss medications at lower price points. Saxenda (liraglutide) is a daily injectable GLP-1 agonist that starts from £135.00, providing a more affordable entry point for patients new to weight loss injections or those preferring daily dosing over weekly administration.

Oral medications such as Orlistat (from £135.00) and Xenical (from £135.00) work through a different mechanism by blocking approximately 30% of dietary fat absorption in the intestines [5]. These tablets are taken three times daily with meals and are particularly suitable for patients who prefer non-injectable treatments or have contraindications to GLP-1 agonists.

The newly available Wegovy Oral Tablets offer semaglutide in pill form from £135.00, providing the clinical benefits of GLP-1 therapy without injections. This oral formulation represents a significant advancement for patients with needle phobia or those seeking the convenience of tablet-based treatment whilst maintaining the efficacy profile of injectable semaglutide.

How to Access Wegovy or Mounjaro Through Cured Pharmacy

Starting your weight loss treatment through Cured Pharmacy takes under three minutes. Complete our free online consultation questionnaire, providing details about your medical history, current medications, weight loss goals, and any previous treatments you've tried. Our UK-registered prescribers review every submission individually to ensure clinical appropriateness and safety.

If approved, your prescription is sent directly to our dispensary where our GPhC-registered pharmacists prepare your medication for dispatch. We use 100% discreet packaging with no external branding, and all orders are shipped via next-day courier with tracking. Your medication arrives in temperature-controlled packaging to maintain efficacy throughout transit.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team remain available for ongoing support throughout your treatment journey. You can contact us on (+44) 116 4646009 with questions about dosing, side effects, or treatment adjustments. Regular follow-up consultations ensure your treatment remains safe and effective as you progress towards your weight loss goals.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Mounjaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg solution for injection in pre-filled pen. GOV.UK. [accessed 13 August 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.